Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05074134 · ClinicalTrials.gov registry record · Phase 1
Absorption, Metabolism, and Excretion Study of [14C]-TNP-2092
A Phase 1 study, sponsored by TenNor Therapeutics Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT05074134: Completed Phase 1 study, sponsored by TenNor Therapeutics Limited.
NCT05074134 is a Phase 1 study that has completed, run by TenNor Therapeutics Limited. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05074134, a Phase 1 study, has completed, sponsored by TenNor Therapeutics Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is an open-label, single dose, Phase 1 study conducted at a single study center in the United States (USA). This study will evaluate the absorption, metabolism and elimination (AME), mass balance, safety and tolerability of a single dose of intravenously administered \[14C\]-TNP-2092. Healthy men aged 18 to 55, will be screened, and subjects who meet all eligibility criteria and provide written informed consent will be enrolled into the study within 28 days of Screening. Subjects will be admitted to the clinical unit on the day prior to dosing (Day -1). Subjects will fast overnight and then given a standard breakfast 30 min prior to dosing. Six subjects will be enrolled in the study and each will receive a single intravenous (IV) dose of 300 mg/3 μCi \[14C\]-TNP-2092 administered over 60 minutes (±10 minutes).
Primary Outcome
Percent (%) for each radiolabeled drug-related material will be determined in plasma,urine and feces.
Interventions
- DRUG [14C]-TNP-2092
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-10-16 |
| Est. Completion | 2022-07-12 |
| Phase | Phase 1 |
What the finished NCT05074134 record still lists
NCT05074134 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which [14C]-TNP-2092 is the first listed.
NCT05074134 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05074134 about?
NCT05074134 is a clinical study titled "Absorption, Metabolism, and Excretion Study of [14C]-TNP-2092". This is an open-label, single dose, Phase 1 study conducted at a single study center in the United States (USA). This study will evaluate the absorption, metabolism and elimination (AME), mass balance, safety and tolerability of a single dose of intravenously administered \[14C\]-TNP-2092. Healthy ...
What is the current status of trial NCT05074134?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2021-10-16. Estimated completion is 2022-07-12.
What interventions are being tested in trial NCT05074134?
The interventions under investigation include: [14C]-TNP-2092 (DRUG).
Who is sponsoring clinical trial NCT05074134?
This trial is sponsored by TenNor Therapeutics Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05074134's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI